BACKGROUND Several inflammatory disorders of the intestine are characterised by enhanced expression of tumour necrosis factor α (TNF-α). Monocytes and macrophages have been suggested as a major cellular source of TNF-α in human gut, whereas mast cells, although known to be capable of producing TNF-α, have been poorly examined in this respect.
AIMS To investigate whether human intestinal mast cells can produce TNF-α, and which factors regulate TNF-α production in these cells.
METHODS Mast cells were isolated from surgery tissue specimens of patients undergoing bowel resection because of cancer. Immunohistochemical studies were performed in biopsy specimens derived from 13 patients (two healthy controls, four with Crohn’s disease, four with ulcerative colitis, three others). TNF-α mRNA and protein expression were studied in vitro by polymerase chain reaction, RNAse protection assay, western blot, and enzyme linked immunosorbent assay in isolated purified human intestinal mast cells stimulated by IgE receptor crosslinking, intestinal bacteria, and lipopolysaccharide. Cellular localisation of TNF-α was examined by immunohistochemistry.
RESULTS TNF-α mRNA and protein were expressed constitutively in isolated human intestinal mast cells. Expression of TNF-α mRNA and release of TNF-α protein were substantially enhanced by IgE receptor crosslinking and by coculture of mast cells with intestinal bacteria; lipopolysaccharide had only marginal effects. Immunohistochemical studies revealed that approximately 60% of the lamina propria cells with immunoreactivity for TNF-α were mast cells.
CONCLUSIONS The data show that mast cells are an important source of TNF-α in the human intestinal mucosa.
- tumour necrosis factor
- mast cells
- inflammatory bowel disease
- inflammatory bowel disease
- mast cell
- stem cell factor
- tumour necrosis factor α
Statistics from Altmetric.com
Tumour necrosis factor α (TNF-α) is a multifunctional cytokine with many proinflammatory and immunoregulatory activities.1 ,2 It is a chemoattractant for neutrophils and monocytes, it increases microvascular permeability, and activates T cells, eosinophils, and mast cells of the skin.1-4Moreover, TNF-α induces endothelial adhesion molecules and thus may initiate the recruitment of circulatory inflammatory cells into the tissue.4 TNF-α is produced by many cell types including monocytes, macrophages, T cells, eosinophils, and mast cells.1 ,5 ,6 In contrast to other cell types, it has been shown in rodents that mast cells store preformed TNF-α in significant quantities and release it on IgE dependent activation.6
A role of TNF-α has been implicated in the pathogenesis of acute inflammatory events caused by Gram negative bacterial infection and of chronic inflammatory disorders such as inflammatory bowel disease (IBD).1 ,2 Interestingly, some evidence derived from animal studies suggests that TNF-α, at low doses, renders a protective effect against bacterial infection, whereas high doses cause tissue destruction and severe clinical symptoms leading to fatal septic shock.7 ,8 In chronic inflammatory diseases, tissue levels of TNF-α are increased; this cytokine has therefore been targeted recently for treatment. Randomised, placebo controlled, double blind clinical trials showed that Crohn’s disease and rheumatoid arthritis can be successfully treated by antagonising TNF-α with chimeric antihuman TNF-α antibody or TNF receptor Fc fusion protein.9 ,10 These studies support the assumption of a fundamental clinical relevance of TNF-α in inflammatory disorders.
Mast cells are tissue cells that exert their biological effects by releasing preformed and de novo synthesised mediators such as histamine, proteases, leukotrienes, prostaglandins, and cytokines on cell activation by IgE receptor crosslinking and other less defined cellular signals.11 ,12 The role of human mast cells in mediating immediate type allergic reactions is well known. In addition, there is increasing evidence that mast cells are involved in chronic inflammatory processes such as IBD, autoimmune diseases, tissue remodelling, and fibrosis.11 ,12 The recognition of mast cells as cytokine producing cells has extended their potential functions from proinflammatory effector cells to regulatory components of the immune system.11 One of the first cytokines found to be produced by mast cells was TNF-α, which was detected primarily in rodent mast cells and mast cell lines.6 In animal models, mast cell derived TNF-α was found to be responsible for the regulation of bacterial infection and for the influx of neutrophils observed during immune complex peritonitis and IgE dependent cutaneous or gastric inflammation.13-15 More recent studies indicated that TNF-α can be also synthesised by human mast cells of the skin, the lung, and the nasal mucosa during allergic responses.16-18 It is questionable whether such data can be extrapolated to the gastrointestinal mucosa, as mast cells derived from different species and different tissues were found to be heterogeneous in terms of morphological, immunohistochemical, and functional criteria.11 ,12 It is not known whether human intestinal mast cells are capable of producing TNF-α, and whether they contribute to the enhanced TNF-α levels found in IBD and other forms of chronic intestinal inflammation. Furthermore, the regulation of TNF-α synthesis and release in human mast cells is largely unclear. To address these questions, we performed immunohistochemical studies using intestinal biopsies and we studied TNF-α mRNA expression and protein release in vitro by human intestinal mast cells using recently established methods.19 ,20
For mast cell isolation, human tissue was obtained from surgical specimens (macroscopically normal border sections, free of tumour cells as determined by histological examination of the tissue) of patients who underwent bowel resection because of intestinal cancer. For immunohistochemical studies, mucosal biopsy specimens derived from 13 patients (four Crohn’s disease, four ulcerative colitis, three intestinal food hypersensitivity, two healthy controls) were examined.
CULTURE MEDIUM AND CELL STIMULI
Cell culture medium consisted of RPMI 1640 without phenol red supplemented with 10% (vol/vol) heat inactivated fetal calf serum, 25 mM HEPES, 2 mM l-glutamine, 100 μg/ml streptomycin, 100 μg/ml gentamycin, 100 U/ml penicillin, and 0.5 μg/ml amphotericin (all cell culture reagents were from Gibco Life Technologies, Paisley, UK). HEPES/albumin (HA) buffer contained 20 mM HEPES (Sigma Chemicals, Steinheim, Germany), and 1 mg/ml bovine serum albumin (Sigma Chemical Co). Human recombinant stem cell factor (SCF) was purchased in lyophilised form (PreproTech Inc., Rocky Hill, New Jersey, USA) and reconstituted in HA buffer at 50 μg/ml. Mast cells were stimulated by IgE receptor crosslinking using the purified monoclonal antibody 29C6 (final concentration 100 ng/ml, provided by Hoffmann-La Roche, Nutley, New Jersey) directed against a non-IgE binding epitope of the high affinity IgE receptor α chain.21 Lipopolysaccharide (LPS) prepared from the Escherichia colistrain 026:B6 (Sigma) was diluted to 1 mg/ml in distilled water and used at a final concentration of 10 μg/ml. Ionomycin and phorbol myristate acetate (PMA) (both from Sigma) were used for cell activation at a final concentration of 1 μM each. The final concentrations of mast cell agonists have been determined as maximally effective concentrations for mast cell activation in previous studies (data not shown). LPS was stored at +4°C. All other cell stimuli were stored at −80°C in small aliquots to avoid freeze-thaw cycles.
ISOLATION AND PURIFICATION OF HUMAN INTESTINAL MAST CELLS
Human mast cells were isolated from intestinal tissue under sterile conditions by a four step enzymatic tissue dispersion method as described in detail previously.13 ,20 The primary cell suspension obtained after cell isolation contained 50–150 × 106 cells, of which approximately 5% were mast cells. Cells were washed, resuspended in culture medium at a cell density of 2 × 106 cells, and cultured overnight in 250 ml standard culture flasks. Mast cells were purified the following day provided that the primary cell suspension contained at least 2 × 106 mast cells. Enrichment of mast cells was achieved by positive selection of mast cells using magnetic cell separation (MACS system, Miltenyi Biotec, Bergisch Gladbach, Germany).20 ,22 Unpurified cells (approximately 108 cells) were harvested from the culture flasks, counted after staining with Tuerk’s solution (Fluka, Buchs, Switzerland), sedimented by centrifugation (300 g, 10 minutes, 4°C), and resuspended in 250 μl of HA buffer containing 5 μg/ml monoclonal antibody YB5.B8 (Pharmingen, Hamburg, Germany) directed against human c-kit.23Cells were incubated with the anti-c-kitmonoclonal antibody for 30 minutes at 4°C with gentle agitation, washed and resuspended in 250 μl HA buffer, and then incubated for 30 minutes at 4°C with 50 μl of goat antimouse IgG antibody coupled to paramagnetic beads (Miltenyi Biotec). After washing in HA buffer, mast cells were enriched by magnetic separation of the cells using a MACS BS column placed in a magnetic field. After separation, cells were washed in culture medium and counted. Cell viability was analysed by staining with trypan blue (Sigma). Percentage of mast cells was evaluated by differential count of cytocentrifuge smears stained with May-Grünwald/Giemsa (Riedel-de Haen, Seelze, Germany). Immunomagnetic separation of mast cells enhanced mast cells purity from 6 (3)% (range 3–13%) to 70 (12)% (range 50–86%; n=13, p<0.001). The recovery of mast cells was 52 (22)%.
MAST CELL CULTURE AND STIMULATION
Purified mast cells were cultured in a humidified atmosphere containing 5% CO2 at 37°C at a density of approximately 0.5 × 106 cells/ml in culture medium supplemented with SCF (25 ng/ml final concentration) using standard multiwell plastic plates.20 In the presence of SCF, mast cells were cultured for up to four weeks without evidence for decreased viability as suggested by morphology, trypan blue staining, and functional properties. The mean (SD) culture time was 13 (8) days (range 5–32 days). Without SCF supplementation, purified mast cells survived in culture for only a few days (data not shown). Cultured mast cells were fed once a week by carefully exchanging half of the culture medium supplemented with SCF. The time interval between the last supplementation with culture medium containing SCF and start of mediator release experiments was at least five days. During cell culture, mast cell purity increased further to 91 (6)% (range 76–100%; n=13, p<0.001). After culture, mast cells were stimulated by different agonists such as monoclonal antibody 29C6, LPS, or intestinal bacteria (see below). Six hours after addition of the mast cell agonists, cells were separated from the supernatant by centrifugation (300 g, 10 minutes, 4°C). The supernatants were stored at −80°C for measurement of cytokines and mediators. Cell pellets were used for RNA and protein extraction.
PREPARATION OF INTESTINAL BACTERIA
In some experiments, a preparation of human intestinal bacteria was used for incubation with cultured mast cells. The preparation of bacteria was obtained from an endogenously infected human intestinal cell culture. The cells were isolated as described from a tissue specimen derived from a 33 year old male patient suffering from polyposis coli without evidence of enteritis or bacterial sepsis. Bacterial infection of mast cells cultured in medium supplemented with different antibiotics was rarely observed. However, in this case, a massive infection of the unpurified intestinal cells had already occurred after overnight culture, and the mast cells examined in the microscope seemed to be activated. The cell supernatants were collected after 16 hours of culture and contained approximately 107bacteria per ml. Microbiological differentiation of the bacteria revealed a mixture of three Gram negative bacterial strains (Escherichia coli,Klebsiella oxytoca, andStenotrophomonas maltophilia, formerly namedXanthomonas maltophilia). For experiments, bacterial suspensions were grown up to a density of 4 × 108 bacteria per ml. Mast cell cultures were challenged for six hours with intestinal bacteria at an initial concentration of 4 × 106 bacteria per ml. Despite supplementation of the culture medium with antibiotics, bacteria stayed alive but hardly expanded.
MEASUREMENT OF MAST CELL MEDIATORS AND CYTOKINES
Histamine was measured in cell free supernatants using a commercially available radioimmunoassay (Coulter-Immunotech, Krefeld, Germany). Sulphidoleukotrienes (sLT) were measured by radioimmunoassay as previously described.24 Histamine release was expressed as ng histamine per 106 mast cells, sLT production as pg sLT per 106 mast cells. TNF-α protein was quantified in cell supernatants by ELISA (R&D Systems, Wiesbaden, Germany). The detection limit of the TNF-α ELISA was 5 pg/ml.
SDS-PAGE AND WESTERN BLOT
TNF-α protein was detected by western blot analysis in cell lysates of purified mast cells (>95% mast cells purity, n=3). Recombinant human TNF-α (0.5 μg, PreproTech) was applied as standard protein. Amersham broad spectrum rainbow marker (Amersham, Little Chalfont, UK) was used as molecular weight marker. Mast cells (106) were harvested and mixed with 10 μl of double concentrated sample buffer (186 mM Tris/HCl at pH 6.8, 20% (wt/vol) glycerol, 4% (wt/vol) sodium dodecyl sulphate (SDS), 0.005 % (wt/vol) bromphenol blue, and 10% (vol/vol) β mercaptoethanol), sonicated for five minutes, and boiled at 95°C for 10 minutes. Protein extracts were separated by SDS polyacrylamide gel electrophoresis (SDS-PAGE).
SDS-PAGE was performed using a mini gel system (Mini-Protean II Cell, Biorad, München, Germany) with 15% running and 5% casting gels (0.75 mm thick) according to Laemmli.25 Samples were run at 100 V for at least two hours at room temperature. Proteins were then blotted on Trans-Blot nitrocellulose foil (Biorad) using a semidry blotting apparatus (Phase, Mölln, Germany) with 45 mA/gel for 45 minutes. The blot foil was saturated in Tris buffered saline with 0.05% Tween 20 at pH 8.0 containing 1% bovine serum albumin (TBST) at 4°C overnight with gentle agitation. A polyclonal rabbit antihuman TNF-α antibody screened for western blots (Genzyme, Cambridge, Massachusetts, USA) was used as a primary antibody at a 1/250 dilution in TBST for one hour at room temperature followed by a one hour incubation with a polyclonal antirabbit IgG antibody labelled with POD at a 1/2000 dilution (Amersham). Two negative controls were included. Firstly, the blot foil was incubated directly with the secondary antirabbit antibody to exclude cross reactivity; secondly, the primary antibody was replaced by a rabbit non-immune serum to exclude unspecific binding of rabbit antibodies to human proteins. The blot was developed with 4-chloro-1-naphtol (Sigma) in phosphate buffered saline (PBS)/methanol.
RNA PREPARATION AND REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION
Total RNA was prepared from human intestinal cell preparations containing 95–100% mast cells using the RNeasy Mini Kit (Qiagen, Hilden, Germany). A yield of approximately 3 μg total RNA was obtained from 106 cells. For reverse transcriptase polymerase chain reaction (RT-PCR), 200 ng of total RNA was treated for 15 minutes at 37°C with 10 U RNAse-free DNAse (Promega, Madison, Wisconsin, USA) to remove genomic DNA. After denaturation for 10 minutes at 70°C, cDNA was synthesised for one hour at 37°C by adding Superscript reverse transcriptase (Life Technologies, Eggenstein, Germany) and 20 pmol oligo dT primers (Pharmacia, Uppsala, Sweden). A 1/10 volume of the cDNA was used for one PCR reaction. PCR was performed with 2.5 U Taq DNA polymerase (Life Technologies) and 20 pmol of the primers (synthesised by Life Technologies) for c-kit (sense: 5′-GGAGATCTG- TGAGAATAGGCTC-3′; antisense: 5′-CCC- ATAGGACCAGACGTCACTTTC-3′) and TNF-α (sense: 5′-GAGCTGAGAGATAAC- CAGCTGGTG-3′; antisense: 5′-CAGATA- GATGGGCTCATACCAGGG-3′) in a reaction volume of 50 μl. Positive controls were performed with primers for GAPDH (sense: 5′-ACCACAGTCCATGCCATCAC-3′; antisense: 5′-TCCACCACCCTGTTGCTGTA-3′). cDNA was amplified using a Peltier thermal cycler (PTC200, MJ Research, Watertown, Massachusetts, USA). Thirty five cycles (60 seconds at 94°C, 80 seconds at 60°C, 70 seconds at 72°C) followed by a five minute extension at 72°C after the last cycle were performed. The PCR products contained transcripts of 354 bp (c-kit), 237 bp (TNF-α), and 452 bp (GAPDH), respectively. An aliquot of the PCR product (10 μl) was separated on 1% agarose gel containing ethidium bromide (500 ng/ml) and photographed. To observe relative changes in mRNA expression of TNF-α the “primer dropping” method was used.26Duplex PCRs were started in the presence of the primer pair for TNF-α. After seven cycles the primer set of GAPDH was added. In each case, 10 μl aliquots of the reactions taken after 29 cycles, 31 cycles, and 33 cycles were separated on 1% agarose gel containing ethidium bromide and analysed using an automated bioimaging analyser (Fuji BAS-1000, Raytest, Germany).
RNAse PROTECTION ASSAY
TNF-α RNA expression in human mast cells was examined using an RNAse protection assay (RNAse Protection Assay System from Promega). The mRNA derived from the human monocytic cell line THP-1 differentiated for 24 hours with 20 μM PMA and stimulated for 24 hours with 300 U/ml interferon γ (PreproTech) was used as a positive control.27 A 354 bp fragment ofc-kit cDNA obtained from a PCR reaction described above was subcloned into a plasmid (pCR-Script SK from Stratagene, La Jolla, California). A cDNA clone of TNF-α in pBluescript KS was kindly provided by C M Gelbmann and S Mestermann (University of Regensburg, Germany). The plasmids were linearised to synthesise radiolabelled antisense cRNA by adding α-32P-UTP (3000 Ci/mmol, Hartmann Analytic, Braunschweig, Germany) and T7 RNA polymerase (Promega), resulting in specific activities of 1–2 × 109 cpm/μg. RNA solution hybridisation was performed using a modified protocol of the manufacturer (Promega). Briefly, 8 μg of total RNA was coprecipitated with 2 × 105 cpm of freshly radiolabelled TNF-α andc-kit cRNA, and then redissolved in 20 μl of 80% deionised formamide containing 1 mM EDTA, 40 mM PIPES, pH 6.4, and 0.2 M sodium acetate. The mixture was denatured at 85°C for five minutes and then annealed at 50°C for 16 hours. After annealing, 180 μl buffer containing 10 U RNAse One (Promega) was added and incubated for one hour at room temperature to digest the unprotected riboprobes. The reaction was stopped by adding SDS to a final concentration of 1%. The protected fragments were precipitated and separated on a 6% polyacrylamide urea gel. The results were analysed by a bioimaging analyser.
IMMUNOHISTOCHEMISTRY AND IMMUNOCYTOCHEMISTRY
Mucosal biopsy specimens were fixed in paraformaldehyde 4% at pH 7.2 for 18–24 hours, embedded in paraffin wax, and sequentially sectioned at 3 μm. Sections were applied to slides coated with 3-aminopropyltriethoxysilan (APES) 0.5% in acetone (Sigma, Deisenhofen, Germany). Slides were dried overnight at 37°C, deparaffinised, and hydrated. Endogenous peroxidase activity was blocked by hydrogen peroxide 3% (10 minutes incubation at room temperature). Cultured cells were harvested, cytocentrifugated on slides, and fixed in acetone 50%/methanol 50% for 10 minutes and in ethanol 70% for 20 minutes. Cytospins were dried for 30 minutes and fixed by hydrogen peroxide 3%/methanol 97%. Immunostaining was performed using LSAB-Kit Universal K680 (Dako Diagnostics, California, USA) for paraffin wax sections and Zymed LAB-SA System (Zymed Laboratories Inc., California, USA) for cytospins.20 ,28The primary antibodies used were mouse antihuman tryptase monoclonal antibody (IgG1; Chemikon, Temecula, California) at 0.28 μg/ml or polyclonal rabbit antiserum directed against human TNF-α (Genzyme, Cambridge, Massachusetts) diluted 1/500 in phosphate buffered saline (PBS). Controls were carried out with non-immune control serum diluted 1/500 in PBS (Immunotech, Marseilles, France) containing IgG1. Slides were counterstained with Mayer’s haemalaun (E. Merck, Darmstadt, Germany) for one minute, blued in tap water for five minutes, and mounted in Kaiser’s glycerol gelatine (E. Merck).
ANALYSIS OF IMMUNOSTAINED SEQUENTIAL SECTIONS
Firstly, 500 lamina propria cells were differentiated to evaluate the percentage of tryptase positive cells (in section no. 1) and TNF-α positive cells (in section no. 2). Secondly, a visible field was selected at ×1000 magnification in section 2, which contained cells staining positive for TNF-α. This area was drawn on paper using a microscope with a drawing tube. Then, the corresponding area in adjacent sections 1 and 3 was adjusted and drawn on the same paper. Using this technique, we quantified lamina propria cells with immunoreactivity for TNF-α, tryptase, or both, respectively. All immunostained sections and cytospins were evaluated by an observer who was not informed about the in vitro study protocols and the clinical data of the patients. We calculated the ratio between TNF-α positive mast cells (Tryp+ TNF+) and total number of mast cells (Tryp+), and the ratio between TNF-α positive mast cells (Tryp+ TNF+) and total number of TNF-α positive cells (TNF+).
Data were expressed as mean (SD), if not indicated otherwise. In addition, the 95% confidence intervals (95% CI) are quoted. The effects of agonists on mast cells were analysed for statistical significance (defined as p<0.05) by the two tailed pairedt test (comparison with buffer control).
TNF-α mRNA IS EXPRESSED IN ISOLATED HUMAN INTESTINAL MAST CELLS
TNF-α mRNA expression in human intestinal mast cells was analysed by RT-PCR in cell preparations containing 95–100% mast cells. The cells had been cultured in the presence of SCF at 25 ng/ml for 5–18 days (n=9 experiments). Using RT-PCR analysis, TNF-α mRNA was detectable in all experiments. The RT-PCR signal for TNF-α was strongly enhanced if mast cells were stimulated for six hours by crosslinking the high affinity IgE receptor with 29C6 prior to cell harvesting and RNA preparation. We could confirm the RT-PCR results using the RNAse protection assay, which has been suggested as a valid method for RNA analysis and requires less amounts of RNA compared with Northern blotting.29 In this experiment, RNA was isolated from 3 × 106 cells (98% mast cells, 2% contaminating fibroblasts) and hybridised with radiolabelled TNF-α andc-kit cRNA. Figure 1A shows that, based on measurements of radioactive signals using an automated bioimaging analyser, TNF-α mRNA was detectable in unstimulated mast cells, and that, in relation to c-kit mRNA levels, it increased twofold in mast cells stimulated with 29C6 for six hours. The experiment was repeated once with a mast cell preparation containing 97% mast cells yielding almost identical results (not shown).
FACTORS ENHANCING TNF-α EXPRESSION BY HUMAN INTESTINAL MAST CELLS
We found that, apart from IgE receptor crosslinking, exposure of the cells for six hours to intestinal bacteria or to LPS also caused an enhancement of TNF-α mRNA expression. The primer dropping method established by Wong and colleagues26 was used to detect relative changes in TNF-α mRNA expression by mast cells cultured under different conditions. Total RNA was prepared from mast cells following stimulation for six hours with 29C6, LPS, or bacteria, respectively, and duplex PCR was performed as described in the Methods section. Figure 1B shows that stimulation with 29C6 or with LPS caused a fourfold increase in TNF-α mRNA expression compared with GAPDH mRNA expression. TNF-α mRNA expression was even more pronounced in mast cells incubated with intestinal bacteria (eightfold increase compared with unstimulated mast cells). The six hour time point for TNF-α mRNA analysis was the most appropriate one to compare the effects of bacteria and LPS with that of 29C6, as enhancement of TNF-α mRNA expression in response to bacteria and LPS was maximal after six hours. However, time course analysis revealed that the increase in TNF-α mRNA expression induced by IgE receptor crosslinking was already maximal after one hour (eightfold increase, data not shown).
These findings were confirmed by immunocytochemical studies showing that challenge of mast cells with 29C6 or intestinal bacteria caused an increase in mast cell percentages with a pronounced immunoreactivity after staining with anti-TNF-α antibody (fig 2). The quantitative evaluation of the cytocentrifuge smears derived from seven experiments revealed that, compared with buffer control (2.7 (2.0)% mast cells with strong TNF-α immunoreactivity; 95% CI 0.9–4.5%), 29C6 (8.5 (4.7)%; 4.1–12.9%) and intestinal bacteria (6.4 (3.5)%; 3.1–9.6%), but not LPS (2.5 (2.9)%; 0–7.0%), induced an enhancement of TNF-α immunoreactivity in mast cells (fig 3).
TNF-α protein expression was further examined by western blot and ELISA in mast cell lysates and supernatants. Figure 4 shows that TNF-α protein was detectable by western blot in lysates of unstimulated purified mast cells and of mast cells stimulated with 29C6 or intestinal bacteria. The size of the TNF-α protein detected in mast cell samples corresponded to that of recombinant TNF-α (17.9 kD) and was located between the 15 kD and 25 kD protein band of the molecular weight marker. No unspecific binding or cross reactivity of the antibodies used for the western blot were observed. Using this technique, no differences in TNF-α protein content could be found between the stimulation protocols. In contrast, measurement of TNF-α protein levels in mast cell lysates and supernatants by ELISA revealed substantial differences (fig 5A). 29C6 as well as bacteria caused an increase in TNF-α protein content in mast cell lysates and supernatants. TNF-α release was most prominent after stimulation of the cells with 29C6. Whereas 29C6 induced significant release of both TNF-α and inflammatory mediators such as histamine and sLT, bacteria caused only TNF-α release and LPS failed to induce significant release of any mediator (fig 5B).
TNF-α PROTEIN SYNTHESIS AND RELEASE BY HUMAN INTESTINAL MAST CELLS IN VIVO
Mucosal biopsy specimens obtained from 13 patients (four with Crohn’s disease, four with ulcerative colitis, three with intestinal food hypersensitivity, two healthy controls) were examined by immunohistological means for TNF-α and tryptase expression in sequential sections (fig 2). Figure 6A shows that the number of tryptase-positive cells (7.5 (3.7)% of lamina propria cells; 95% CI 5.8–9.8%; n=13) counted in section 1 correlated with the number of TNF-α positive cells (2.5 (1.8)%; 1.4–3.5%; n=13). Analysis of sequential sections revealed that 60 (40)% (95% CI 35–84%) of the TNF-α positive cells within the lamina propria were tryptase positive mast cells, and 26 (28)% (95% CI 10–43%) of the mast cells were positive for TNF-α. No significant differences in numbers of tryptase positive cells (p=0.07, one way analysis of variance) and TNF-α positive cells (p=0.12) were found between healthy controls and patients with Crohn’s disease, ulcerative colitis, and food allergy (fig 6B). As not all biopsy specimens derived from patients had histological signs of active inflammation such as epithelial destruction and leucocyte infiltration, specimens were divided into histologically normal (n=6; two healthy controls, one Crohn’s disease, three food allergy) and inflamed (n=7; three Crohn’s disease, four ulcerative colitis) biopsy specimens. The numbers of tryptase positive cells and TNF-α positive cells, respectively, were similar in histologically inflamed and normal tissue. However, the percentages of TNF-α positive mast cells and the percentage of tryptase positive TNF producing cells were slightly higher in inflamed tissue compared with macroscopically normal tissue, although the differences were not statistically significant (t test, p>0.05; fig 6C).
Our data indicate that human intestinal mast cells are a major source of TNF-α in the gastrointestinal tract. Furthermore, they extend previous studies showing that human mast cells of the skin and the respiratory tract are capable of producing TNF-α both in vitro on stimulation by IgE receptor crosslinking and in vivo in the course of allergic and other mast cell associated diseases to those from the human gastrointestinal tract.17-19 The knowledge that mast cells can synthesise and release TNF-α was based originally on findings in rodents and had to be confirmed for the human system, as many previous studies showed that rodent mast cells and human mast cells may differ substantially in functional respects.6 ,11 For example, rodent mast cells express the interleukin 3 (IL-3) receptor and IL-3 is an important growth factor for rodent mast cells, whereas human mast cells lack the IL-3 receptor.30 Furthermore, within the human system, mast cells exert a considerable heterogeneity based on morphological, biochemical, and functional criteria. According to the protease content, three types of human mast cells (MC) have been described (MCT, containing tryptase but no chymase; MCTC, containing both tryptase and chymase; and MCC, containing chymase but no tryptase), which are present in various degrees in the intestinal tract (mucosa, 58% MT, 35% MCTC, 7% MCC; submucosa, 83% MCTC, 17% MCC).31 Recently, it was shown that the classification of mast cells into different phenotypes may be of functional relevance, as MCTC produce cytokines (preferentially IL-4) other than MCT (IL-5 and IL-6).32 It is unclear whether the production of TNF-α can also be attributed to a particular mast cell subtype, as intestinal mast cell preparations contain different mast cell subtypes, which cannot be separated in vitro. However, it is tempting to speculate that both MCTC and MCT may produce TNF-α, because human skin mast cells (which consist almost exclusively of MCTC) and rodent gastral mast cells (which are believed to be equivalents of human MCT) have been shown to produce TNF-α.16 ,17
To date, the ability of gastrointestinal mast cells to produce cytokines such as TNF-α has hardly been studied. Apart from a study by Beil et al, who showed by electron microscopy that in Crohn’s disease TNF-α immunoreactivity was localised in intestinal mast cells, we are not aware of studies examining cytokine production in human intestinal mast cells.33 This is surprising, as it is known from many studies that TNF-α is expressed in human gastrointestinal mucosa, and that the expression is strongly enhanced in the course of inflammatory diseases such as Crohn’s disease or ulcerative colitis.2 ,34 ,35 TNF-α production in the human gut has been attributed to monocytes, macrophages, natural killer cells, and T lymphocytes, but not to mast cells.1 ,2 ,35 Our immunohistochemical studies, however, clearly show that human mucosal mast cells produce TNF-α. We found no significant differences in TNF immunoreactivity between IBD patients and controls, which does not contradict previous findings, as immunohistochemistry is a delicate method for quantitative studies, and the number of patients we examined was rather small. Of particular interest is our finding that approximately 60% of all lamina propria cells expressing TNF-α protein were mast cells, which indicates that mast cells are of considerable relevance within the cell types producing TNF-α in the human intestinal mucosa. It is unclear at present, to what extent mast cells besides other cell types contribute to an enhanced TNF-α production in inflammatory disease states. This may differ depending on the aetiology of the inflammatory disorder.7 ,8 ,16
To address the question of how TNF-α production is regulated in human intestinal mast cells, we performed in vitro studies with isolated purified mast cell preparations. We found that not only IgE receptor crosslinking by anti-IgE receptor antibody, as shown previously in rodent mast cells6 ,36 and human skin mast cells,17 ,37 but also bacterial products activate human intestinal mast cells for enhanced TNF-α production. The first evidence for the induction of TNF-α synthesis in mast cells by bacterial products came from animal studies.7 ,8 Malaviyaet al, who infected animals with a mouse virulent strain of Klebsiella pneumoniae, found that purified mouse mast cells release TNF-α on incubation with bacteria and that the type 1 fimbrial subunit, FimH, was the necessary enterobacterial component for mast cell activation.8 We incubated human intestinal mast cells with a preparation containing the enterobacterial strains Escherichia coli,Klebsiella oxytoca, andStenotrophomonas maltophilia, and found that these bacteria significantly enhance the synthesis of TNF-α. Similar to 29C6, which crosslinks the high affinity IgE receptor on mast cells, the bacteria induced an increase in both TNF-α mRNA expression and protein synthesis and release. It is unclear whether bacterial antigen triggers mast cells by binding to and crosslinking surface bound IgE molecules or by IgE independent mechanisms. The fact that the mast cells used for experiments were isolated by enzymatic digestion of intestinal tissue and cultured for several days prior to stimulation, makes it unlikely that they have preserved IgE molecules on their surface and hence suggests an IgE independent mechanism. This hypothesis is supported by the finding that the bacterial product LPS was also capable of enhancing TNF-α mRNA expression, but no significant TNF-α protein release, in human intestinal mast cells. LPS is also known to activate monocytes and macrophages for the production of TNF, and therefore represents an important factor regulating TNF-α production in different cell types in an IgE independent manner.38 Apart from LPS, other bacterial derived factors seem to be involved in the regulation of TNF-α in mast cells.
In previous studies, we and others have shown that IgE receptor crosslinking causes the release of inflammatory mediators such as histamine or leukotrienes from human mast cells, and that the release reaction is enhanced in the presence of SCF, thec-kit ligand.13 ,39 Here we found that the release of preformed histamine and de novo synthesised sLT one the one hand, and TNF-α on the other, is regulated differently in human intestinal mast cells. 29C6 caused the release of histamine, sLT, and TNF-α, whereas bacteria caused TNF-α release, but no sLT and only marginal histamine release. Similar results were reported for rat peritoneal mast cells which produce IL-6, but only marginal histamine release in response to LPS.40 SCF neither caused nor enhanced TNF-α release (data not shown), confirming previous studies performed in rat mast cells.41The hypothesis of a different regulation of TNF-α and histamine/sLT release in mast cells is supported by the recent study of Tashiroet al who showed that in murine mast cells triggered by IgE receptor crosslinking, the secretion of TNF-α, but not of histamine or eicosanoids, is enhanced by costimulation of the cells via the CD 28 molecule.36
The clinical consequences of TNF-α production by human intestinal mast cells are yet unclear. TNF-α may have beneficial as well as pathological functions depending on its concentration and on the kind of disease. Some studies performed in mouse models of acute bacterial infection, which have to be confirmed for the human situation, indicate a protective role of TNF-α derived from mast cells, whereas TNF-α is believed to be responsible for tissue infiltration with neutrophils and other inflammatory cells and subsequent tissue destruction in the course of chronic inflammatory diseases such as IBD.2 ,7 ,8 Several studies derived from the rodent system indicate that the production of TNF-α by mast cells can be influenced by pharmacological interventions, which suggests new strategies for the treatment of diseases associated with mast cells and TNF-α. For example, it was shown that IL-10 inhibits TNF-α production in mast cells without affecting preformed histamine release.42 ,43This may be of particular interest for IBD, as preliminary clinical trials have been carried out showing that patients with Crohn’s disease can be successfully treated by parenteral administration of IL-10.44 Furthermore, the classical drugs used for treatment of IBD, glucocorticosteroids and sulphasalazine, as well as interferon, also inhibit IgE dependent release of TNF-α and mediators by mast cells.45-47 These studies provide new insights into the mode of action of some drugs and, if the findings can be confirmed in future studies for human mast cells, they may be of particular clinical relevance for the treatment of allergic and other inflammatory diseases.
The authors thank Ms Anita Schmeil for technical assistance, Dr Michael Martin, Department of Molecular Pharmacology, for measurement of cytokines, and Dr Susanne Häusler, Department of Microbiology, for characterisation of intestinal bacteria. The study was supported by grant no SFB280-C8 from the Deutsche Forschungsgemeinschaft to SCB.
- inflammatory bowel disease
- mast cell
- stem cell factor
- tumour necrosis factor α
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.